Skip to main content
EMVISION MEDICAL DEVICES LTD logo

EMVISION MEDICAL DEVICES LTD — Investor Relations & Filings

Ticker · EMV ISIN · AU0000028375 ASX Manufacturing
Open in API
Filings indexed 304 across all filing types
Latest filing 2022-05-03 Capital/Financing Update
Country AU Australia
Listing ASX EMV

About EMVISION MEDICAL DEVICES LTD

https://emvision.com.au/

EMVision Medical Devices Ltd is a medical technology company focused on the development and commercialization of portable medical imaging devices. The company specializes in electromagnetic microwave imaging technology designed for the rapid diagnosis and monitoring of stroke and traumatic brain injury. Its primary product is a portable brain scanner intended for use at the point of care, including intensive care units, emergency departments, and ambulances. By utilizing non-ionizing radiation, the technology provides a safe, cost-effective, and mobile alternative to traditional neuroimaging modalities like CT and MRI. The device aims to facilitate earlier clinical intervention by enabling bedside assessment, potentially improving patient outcomes through faster detection of ischemic and hemorrhagic strokes.

Recent filings

Filing Released Lang Actions
EMVision Secures Strategic Agreement With Keysight 4 pages 281.4KB
Capital/Financing Update Classification · 90% confidence The document is a press release announcing a strategic agreement between EMVision Medical Devices Ltd and Keysight Technologies. It details the terms of the agreement, the technology involved, and includes forward-looking statements. There are no financial statements, regulatory certifications, voting results, or management changes. The content focuses on a business partnership and technology collaboration, which fits the category of a Capital/Financing Update or strategic business update. However, since it is about a strategic agreement related to product development and commercialisation rather than fundraising or capital structure changes, the best fit is Capital/Financing Update (CAP). The document length is over 10,000 characters and contains substantive information about the agreement, not just an announcement of a report or certification, so it is not RPA or RNS.
2022-05-03 English
Trading Halt 2 pages 600.8KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from EMVision Medical Devices Ltd regarding a trading halt requested under ASX Listing Rule 17.1. It states that trading in the company's securities will be halted pending a forthcoming announcement about a strategic agreement. The document does not contain financial data, report content, or detailed disclosures but is a brief notice about the trading halt itself. It is short (1835 characters) and serves as an announcement rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-05-01 English
Quarterly Activities/Appendix 4C Cash Flow Report 9 pages 285.0KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'APPENDIX 4C – 31 MARCH 2022 QUARTERLY ACTIVITIES & CASHFLOW REPORT' and provides detailed commentary on the company's quarterly activities, cash flow, and operational progress for the quarter ending 31 March 2022. It includes financial data such as cash reserves, operating cash outflows, and funding received during the quarter. The document is approximately 15,000 characters long, indicating it is a substantive report rather than a brief announcement. The content focuses on quarterly operational and financial performance, consistent with an Interim / Quarterly Report. There is no indication that this is an Annual Report, Earnings Release, or other filing types. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). 9M 2022
2022-04-28 English
New Appointments to Clinical Advisory Board 2 pages 168.8KB
Board/Management Information Classification · 95% confidence The document is a press release announcing the appointment of Professors Donnan, Davis, and Dr Dos Santos to the Clinical Advisory Board of EMVision Medical Devices Ltd. It focuses on management and advisory board changes, describing the qualifications and roles of the new members. There is no financial data, no mention of financial results, no regulatory filings, no voting results, no capital changes, and no legal proceedings. The content is about changes in senior advisory personnel, which fits the category of Board/Management Information (MANG). The document length is 8014 characters, which is sufficient for a full announcement rather than a brief note. Therefore, the appropriate classification is MANG with high confidence.
2022-03-08 English
Half Yearly Report and Accounts 19 pages 809.9KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'EMVision Medical Devices Ltd Appendix 4D Half-year report' and references the half-year ended 31 December 2021. It contains detailed financial data including income, loss, cash flows, net assets, and directors' report. It also includes an auditor's review report and financial statements such as statement of profit or loss, statement of financial position, and cash flows. The document is comprehensive and covers a period shorter than a full fiscal year, consistent with an interim or quarterly report. The presence of detailed financial statements and analysis confirms it is not merely an announcement or a certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2022
2022-02-23 English
CEO Half-Year Update 4 pages 183.7KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'CEO HALF-YEAR UPDATE' and mentions the release of an Appendix 4D and Interim Report for the half-year ended 31 December 2021. It contains detailed operational updates, clinical trial progress, funding information, and forward-looking statements. The content includes substantive financial and business information relevant to a half-year period, not just a brief announcement or summary. The length of the document (over 13,000 characters) and the detailed nature of the content indicate it is a comprehensive interim report rather than a simple announcement or regulatory filing. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2022
2022-02-23 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.